Last year: How much is bet on March Madness? 2022 tournament could be biggest betting event in history Provided by Dow Jones Mar 21, 2022 4:21 PM UTC By Weston Blasi Since last year's tournament, more U.S. states have legalized mobile sports betting The 2022 men's March Madness tournament will likely be the biggest sports betting event in U.S. history. According to estimates from PlayUSA, $3 billion is expected to be legally wagered during this year's college basketball tournament, doubling totals from 2021. ___________________________ This year: This is How Much Money is Expected to be Bet on 2023 March Madness Written by: Don Shapiro Published on: Mar/13/2023 “March Madness is one of the best traditions in American sports—and America’s most wagered-on competition. Critically, the expansion of regulated sports betting over the past five years has brought safeguards to more than half of American adults who can now bet legally in their home market.” - AGA President and CEO Bill Miller. How much will be bet during the 2023 NCAA Men's Tournament? A quarter of all American adults (68 million) plan to wager $15.5 billion on this year’s NCAA Men’s Division I Basketball Tournament, according to a new survey from the American Gaming Association (AGA). Amazingly, three fourths of those surveyed say this will be their first time betting on March Madness online. ______________________________________ ______________________________________ $3B to $15B in one year. On one tournament. Sports betting is exploding obviously. FWIW... SRAD is not a betting website... they sell the picks and shovels to those websites. They wrote the book on in-app betting. This stock is sooo underappreciated. Or undiscovered. IPO'd in 9/21 at $28 ---- refused to be SPAC'd Projected EPS growth for the next 5 years: 170% QoQ revenue growth 30%+ They went cashflow positive last quarter. No debt $300M cash $3B marketcap FW PE 60 P/S (ttm) 4.6 EV/EBITDA ~14 No insider sales. Swiss company 76% gross margin last Q 7% net margin As a software company, that net margin should only improve. #1 provider of B2B solutions to the sports betting industry worldwide. Odds, risk management, traffic generation, play by play betting... the whole 9 yards. Or so they say. $11.76 close today. Earnings tomorrow.
Here comes "the contagion is doing Powell's job for him" mantra. -Again. Quick cnbc.... wake up Cashin. SRAD up on earnings. Profit decreased, fcf went to the moon. I hope they don't have money in Credit Suisse though.
Good morning. If it can be good. It's never a positive event when I have an 8:30 meeting uptown./// Lost of moving parts. Credit Suiss etc. The HF has some aggressive types who want to take advantage of the banking dislocation- they may do so -- Personally, I'd rather wait til the dust settles. Gold is through the Fing* roof. My poor wife makes jewelry. Silver anyone-? My best advice is think quality: We have two major stocks that are basing and I feel are good buys DIS & RH. If you use yesterdays lows on each name, I think they will close above today. Create positions in these names as the shoulders to build on for future portfolios. I have a phone conf with Big Pete and crew and will touch base at 11:30>
Abbreviated)))))))))))))))))))))))))) --Smartsheet rises 13.5% 09:47 SMAR --Liberty Formula One price target raised to $60 from $56 at Deutsche Bank 09:19 FWONA --Bank OZK upgraded to Buy from Neutral at UBS 08:53 OZK --Webster Financial initiated with a Buy at UBS 09:07 WBS
This is kind of interesting-- Higher doses can bring greater results / and more side effefcts it cuts both ways but often you get abetter read out. Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome Wed, March 15, 2023, 7:00 AM EDT In this article: STOK -4.22% – Dosing anticipated to start in the coming weeks – – Company remains on track for its planned data readouts from the Phase 1/2a MONARCH and ADMIRAL studies in 2023 – BEDFORD, Mass., March 15, 2023--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that the FDA will allow the administration of a higher single dose of STK-001 (70mg) in its ongoing Phase 1/2a MONARCH study of children and adolescents with Dravet syndrome. This new 70mg single dose cohort in MONARCH will complement the ongoing evaluation of multiple doses of 70mg in the ADMIRAL study. Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures beginning within the first year of life. Complications of the disease often contribute to poor quality of life for patients and their caregivers. Despite available anti-seizure medicines, seizures are not adequately controlled for more than 90% of patients. STK-001 is a proprietary antisense oligonucleotide (ASO) being developed by Stoke as the first potential new medicine to address the genetic cause of Dravet syndrome. "There is an urgent need for a disease modifying approach to treat Dravet syndrome, a devastating disease with effects that go beyond seizures and impact quality of life for patients and their families," said Barry Ticho, M.D., Ph.D., Chief Medical Officer of Stoke Therapeutics. "We thank the FDA for its timely review of the clinical data from our ongoing studies. We expect data from this new dose cohort to provide information about the potential effects and durability of a single dose of 70mg. We look forward to dosing the first patient in the coming weeks and to be able to include preliminary findings in our anticipated data readout in the second half of 2023." Upcoming Anticipated Milestones Data from patients treated with multiple 45mg doses of STK-001 are anticipated in mid-2023. Data from patients treated with 70mg of STK-001 in MONARCH (single dose) and ADMIRAL (multiple doses) are anticipated in the second half of 2023. The Company expects to complete the Phase 1/2a studies of STK-001 in 2023 in order to initiate a Phase 3 program in 2024. The MONARCH study remains on partial clinical hold for multiple doses of STK-001 above 45mg. About Dravet Syndrome Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures, beginning within the first year of life. Dravet syndrome is difficult to treat and has a poor long-term prognosis. Complications of the disease often contribute to a poor quality of life for patients and their caregivers. The effects of the disease go beyond seizures and often include intellectual disability, developmental delays, movement and balance issues, language and speech disturbances, growth defects, sleep abnormalities, disruptions of the autonomic nervous system and mood disorders. The disease is classified as a developmental and epileptic encephalopathy due to the developmental delays and cognitive impairment associated with the disease. Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP. There are no approved disease-modifying therapies for people living with Dravet syndrome. One out of 16,000 babies are born with Dravet syndrome, which is not concentrated in a particular geographic area or ethnic group. About STK-001 STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials. Stoke believes that STK-001, a proprietary antisense oligonucleotide (ASO), has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome. STK-001 is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both occurrence of seizures and significant non-seizure comorbidities. STK-001 has been granted orphan drug designation by the FDA and the EMA, and rare pediatric disease designation by the FDA as a potential new treatment for Dravet syndrome.
Stoke Therapeutics, Inc. (STOK) Put on watch/ NasdaqGS - NasdaqGS Real Time Price. 9.37-0.46 (-4.68%) As of 09:59AM EDT.
Gummy-Sportradar Group AG (SRAD) (Go Small 150 shares) NasdaqGS - NasdaqGS Real Time Price. 10.48-1.28 (-10.92%)<----- GO Time-! As of 10:00AM EDT.
Pattern Bearish Sportradar AG Full Year 2022 revenue growth of 30% exceeds annual 2022 outlook Fourth quarter ROW Betting segment revenue grew 29% with Adjusted EBITDA margin of 44% Fourth quarter U.S. segment revenue grew 77%; positive Adjusted EBITDA for second consecutive quarter 2023 annual outlook with growth of 24% to 26% for revenue and 25% to 33% for Adjusted EBITDA